

Stresam is a non-sedating tranquilizer drug that is used to treat anxiety. Although not being a benzodiazepine, its anxiolytic effect is comparable to that of lorazepam. Several studies also suggest that tofisopam has neurotrophic action, and potentially can be used in peripheral nerve injury
Stresam is a non-benzodiazepine anxiolytic drug, prescribed in France since 1979 for psychosomatic manifestations of anxiety. The active ingredient of Stresam is Etifoxine.
Its anxiolytic properties have been shown in rodents: etifoxine reduces stress-induced physiological and endocrine modifications, like hyperthermia, activation of colonic activity. Binding and electrophysiological experiments have demonstrated that etifoxine enhances the inhibitory GABAergic system notably implied in the regulation of anxiety, as do benzodiazepines, barbiturates and neurosteroids, by different ways.
It has an affinity with chloride channel coupled to the GABAA receptor complex, and binds to these receptors via an allosteric site distinct from benzodiazepines. Indeed, it has been shown that etifoxine preferentially acts on GABAA receptors containing the b2 or b3 subunit. The second way might involve the stimulation of mitochondrial-type benzodiazepine receptors known to control neurosteroid synthesis like allopregnanolone, also positive modulator of GABAA receptors with anxiolytic-like properties.
As sedative properties of benzodiazepines are mediated by the GABAA receptor alpha1 subtype, etifoxine, with regard to its pharmacological profile, might be distinguished from benzodiazepines in general in terms of its clinical effects and safety. In humans, its efficacy in the treatment of anxiety disorders has previously been shown in a double-blind controlled study. Compared to lorazepam, a short-acting BZD (elimination half-life of 12 h), no impairment in vigilance, mnesic or psychomotor performance was revealed in healthy young subjects receiving single oral doses of stresam (50 and 100 mg).
No customer reviews for the moment.
Orally, with a little water.
The dose of the drug is determined by the doctor, individually, depending on the condition of the patient.
Usually it is prescribed 1 capsule 3 times a day, or 2 capsules 2 times a day. (150-200 mg / day)
The duration of treatment is from several days to 4-6 weeks, depending on the condition of the patient.
The following are the undesirable phenomena (AEs) that were noted when taking this drug, according to the classification by system organ class and frequency of occurrence (“rare”: ≥1 / 10 000 and <1/1000, “very rare”:
<1/10 000) in decreasing order of frequency.
Nervous system disorders
Rarely: slight drowsiness that appears in the first days of treatment and usually disappears on its own during treatment.
Violations of the skin and subcutaneous tissue
Rarely: skin reactions: maculopapular rash, erythema multiforme, pruritus, swelling of the face.
Very rarely: allergic reactions: urticaria, angioedema.
Frequency is not established: anaphylactic shock, drug-induced hypersensitivity syndrome with eosinophilia, Stevens-Johnson syndrome, leukocytoclastic vasculitis.
Disorders of the liver and biliary tract
Frequency is not installed: hepatitis, cytolytic hepatitis.
Disorders of the genitals and breast
Frequency is not installed: metrorrhagia in women taking oral contraceptives.
Disorders of the gastrointestinal tract
Frequency not established: lymphocytic colitis.
Hypersensitivity to the active ingredient or another component of the drug, shock, myasthenia gravis, severe disorders of the liver and / or kidneys. Due to the presence of lactose in the preparation, the drug should not be used in galactosemia, glucose and galactose malabsorption syndrome, as well as in the case of lactase deficiency.
Not recommended for use under the age of 18 years.
potentiates the action of drugs that depress the central nervous system, such as opioid analgesics, barbiturates, sleeping pills, antihistamines, antipsychotics, etc. Also enhances the effects of alcohol.
It is not recommended to use the drug during pregnancy. If you detect pregnancy while taking the drug, you should consult with your doctor about the continuation of treatment.
It is not recommended to use the drug when breastfeeding.
If you experience skin or allergic reactions, as well as complications of the liver, the drug should be stopped.
In case of skipping the drug intake, do not double the dose at the next dose.
In connection with the risk of drowsiness, it is necessary during the treatment to avoid driving vehicles and activities requiring increased attention, for example, controlling various mechanisms.
IT IS NOT RECOMMENDED TO TAKE THE DRUG TOGETHER WITH ALCOHOLIC BEVERAGES.
DO NOT EXCEED THE PRESIGNED DOCTOR.
Symptoms: lethargy, excessive drowsiness. Treatment: If necessary, have symptomatic treatment. The specific antidote is absent.
Studies and clinical trials of Etifoxine (Click to expand)